These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 24900864)

  • 41. Orally active ghrelin receptor inverse agonists and their actions on a rat obesity model.
    Takahashi B; Funami H; Iwaki T; Maruoka H; Shibata M; Koyama M; Nagahira A; Kamiide Y; Kanki S; Igawa Y; Muto T
    Bioorg Med Chem; 2015 Aug; 23(15):4792-4803. PubMed ID: 26100441
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Small-molecule ghrelin receptor antagonists improve glucose tolerance, suppress appetite, and promote weight loss.
    Esler WP; Rudolph J; Claus TH; Tang W; Barucci N; Brown SE; Bullock W; Daly M; Decarr L; Li Y; Milardo L; Molstad D; Zhu J; Gardell SJ; Livingston JN; Sweet LJ
    Endocrinology; 2007 Nov; 148(11):5175-85. PubMed ID: 17656463
    [TBL] [Abstract][Full Text] [Related]  

  • 43. C-terminus of a hexapeptidic ghrelin receptor inverse agonist can switch peptide behavior from inverse agonism to agonism.
    Els-Heindl S; Bellmann-Sickert K; Beck-Sickinger AG
    Biopolymers; 2016 Jan; 106(1):101-8. PubMed ID: 26566778
    [TBL] [Abstract][Full Text] [Related]  

  • 44. GABAA receptor subtype-selective modulators. II. α5-selective inverse agonists for cognition enhancement.
    Atack JR
    Curr Top Med Chem; 2011; 11(9):1203-14. PubMed ID: 21050171
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Obestatin stimulates glucose-induced insulin secretion through ghrelin receptor GHS-R.
    Pradhan G; Wu CS; Han Lee J; Kanikarla P; Guo S; Yechoor VK; Samson SL; Sun Y
    Sci Rep; 2017 Apr; 7(1):979. PubMed ID: 28428639
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Discovery of MK-8282 as a Potent G-Protein-Coupled Receptor 119 Agonist for the Treatment of Type 2 Diabetes.
    Neelamkavil SF; Stamford AW; Kowalski T; Biswas D; Boyle C; Chackalamannil S; Xia Y; Jayne C; Neustadt B; Hao J; Liu H; Dai X; Baker H; Hawes B; O'Neill K; Tang H; Greenlee WJ
    ACS Med Chem Lett; 2018 May; 9(5):457-461. PubMed ID: 29795759
    [TBL] [Abstract][Full Text] [Related]  

  • 47. GPR40-Mediated G
    Rives ML; Rady B; Swanson N; Zhao S; Qi J; Arnoult E; Bakaj I; Mancini A; Breton B; Lee SP; Player MR; Pocai A
    Mol Pharmacol; 2018 Jun; 93(6):581-591. PubMed ID: 29572336
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Synthesis and biological evaluation of an orally active ghrelin agonist that stimulates food consumption and adiposity in rats.
    Lugar CW; Clay MP; Lindstrom TD; Woodson AL; Smiley D; Heiman ML; Dodge JA
    Bioorg Med Chem Lett; 2004 Dec; 14(23):5873-6. PubMed ID: 15501059
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Discovery of MK-3207: A Highly Potent, Orally Bioavailable CGRP Receptor Antagonist.
    Bell IM; Gallicchio SN; Wood MR; Quigley AG; Stump CA; Zartman CB; Fay JF; Li CC; Lynch JJ; Moore EL; Mosser SD; Prueksaritanont T; Regan CP; Roller S; Salvatore CA; Kane SA; Vacca JP; Selnick HG
    ACS Med Chem Lett; 2010 Apr; 1(1):24-9. PubMed ID: 24900170
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Design and synthesis of a novel series of orally active, selective somatostatin receptor 2 agonists for the treatment of type 2 diabetes.
    Banno Y; Sasaki S; Kamata M; Kunitomo J; Miyamoto Y; Abe H; Taya N; Oi S; Watanabe M; Urushibara T; Hazama M; Niwa SI; Miyamoto S; Horinouchi A; Kuroshima KI; Amano N; Matsumoto SI; Matsunaga S
    Bioorg Med Chem; 2017 Nov; 25(21):5995-6006. PubMed ID: 28988629
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Ghrelin receptor: high constitutive activity and methods for developing inverse agonists.
    Els S; Beck-Sickinger AG; Chollet C
    Methods Enzymol; 2010; 485():103-21. PubMed ID: 21050913
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Discovery of [1,2,4]Triazolo[1,5-
    Nakajima R; Oono H; Sugiyama S; Matsueda Y; Ida T; Kakuda S; Hirata J; Baba A; Makino A; Matsuyama R; White RD; Wurz RΡ; Shin Y; Min X; Guzman-Perez A; Wang Z; Symons A; Singh SK; Mothe SR; Belyakov S; Chakrabarti A; Shuto S
    ACS Med Chem Lett; 2020 Apr; 11(4):528-534. PubMed ID: 32292560
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Discovery of a potent, selective and orally bioavailable 3,9-diazaspiro[5.5]undeca-2-one CCR5 antagonist.
    Yang H; Lin XF; Padilla F; Gabriel SD; Heilek G; Ji C; Sankuratri S; deRosier A; Berry P; Rotstein DM
    Bioorg Med Chem Lett; 2009 Jan; 19(1):209-13. PubMed ID: 19014885
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Discovery of AM-1638: A Potent and Orally Bioavailable GPR40/FFA1 Full Agonist.
    Brown SP; Dransfield PJ; Vimolratana M; Jiao X; Zhu L; Pattaropong V; Sun Y; Liu J; Luo J; Zhang J; Wong S; Zhuang R; Guo Q; Li F; Medina JC; Swaminath G; Lin DC; Houze JB
    ACS Med Chem Lett; 2012 Sep; 3(9):726-30. PubMed ID: 24900539
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Evaluation and synthesis of polar aryl- and heteroaryl spiroazetidine-piperidine acetamides as ghrelin inverse agonists.
    Orr ST; Beveridge R; Bhattacharya SK; Cameron KO; Coffey S; Fernando D; Hepworth D; Jackson MV; Khot V; Kosa R; Lapham K; Loria PM; McClure KF; Patel J; Rose C; Saenz J; Stock IA; Storer G; von Volkenburg M; Vrieze D; Wang G; Xiao J; Zhang Y
    ACS Med Chem Lett; 2015 Feb; 6(2):156-61. PubMed ID: 25699143
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Discovery of a thieno[2,3-d]pyrimidine-2,4-dione bearing a p-methoxyureidophenyl moiety at the 6-position: a highly potent and orally bioavailable non-peptide antagonist for the human luteinizing hormone-releasing hormone receptor.
    Sasaki S; Cho N; Nara Y; Harada M; Endo S; Suzuki N; Furuya S; Fujino M
    J Med Chem; 2003 Jan; 46(1):113-24. PubMed ID: 12502365
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Endogenous ghrelin in pancreatic islets restricts insulin release by attenuating Ca2+ signaling in beta-cells: implication in the glycemic control in rodents.
    Dezaki K; Hosoda H; Kakei M; Hashiguchi S; Watanabe M; Kangawa K; Yada T
    Diabetes; 2004 Dec; 53(12):3142-51. PubMed ID: 15561944
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Anamorelin HCl (ONO-7643), a novel ghrelin receptor agonist, for the treatment of cancer anorexia-cachexia syndrome: preclinical profile.
    Pietra C; Takeda Y; Tazawa-Ogata N; Minami M; Yuanfeng X; Duus EM; Northrup R
    J Cachexia Sarcopenia Muscle; 2014 Dec; 5(4):329-37. PubMed ID: 25267366
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Discovery of Potent, Selective, and Orally Bioavailable Estrogen-Related Receptor-γ Inverse Agonists To Restore the Sodium Iodide Symporter Function in Anaplastic Thyroid Cancer.
    Kim J; Song J; Ji HD; Yoo EK; Lee JE; Lee SB; Oh JM; Lee S; Hwang JS; Yoon H; Kim DS; Lee SJ; Jeong M; Lee S; Kim KH; Choi HS; Lee SW; Park KG; Lee IK; Kim SH; Hwang H; Jeon YH; Chin J; Cho SJ
    J Med Chem; 2019 Feb; 62(4):1837-1858. PubMed ID: 30657313
    [TBL] [Abstract][Full Text] [Related]  

  • 60. IA-2beta, but not IA-2, is induced by ghrelin and inhibits glucose-stimulated insulin secretion.
    Doi A; Shono T; Nishi M; Furuta H; Sasaki H; Nanjo K
    Proc Natl Acad Sci U S A; 2006 Jan; 103(4):885-90. PubMed ID: 16418280
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.